688468.SHG Chemclin Diagnostics Co. Ltd. A
- Market cap
- CNY 2.33B
- P/E
- 72.5x
- P/B
- 1.61x
- ROE
- 2.2%
- Dividend yield
- 2.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688468.SHG undervalued?
Graham number688468.SHG trades 127.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chemclin Diagnostics Co. Ltd. A fundamental analysis
No fundamental analysis for Chemclin Diagnostics Co. Ltd. A yet.
Chemclin Diagnostics Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sale of clinical immuno chemiluminescence diagnostic reagents and instruments in China. The company offers the LiCA series of diagnostic reagents, which is based on photo-induced chemiluminescence; the Chemclin series of diagnostic reagents and instruments, which is based on enzyme-catalyzed chemiluminescence; and routine clinical chemistry diagnostic reagents. Its products are used for the …
Full company profileChemclin Diagnostics Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chemclin Diagnostics Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 319M | 366M | 455M | 418M | 471M | 465M | 445M | 436M | 333M | 309M |
| Gross Profit | 228M | 264M | 342M | 301M | 351M | 344M | 335M | 323M | 221M | 186M |
| Operating Income | -420M | -412M | 160M | 137M | 163M | 170M | 166M | 135M | 50.3M | 27.2M |
| EBITDA | -382M | -374M | 201M | 178M | 206M | 218M | 204M | 189M | 50.3M | 42.6M |
| Net Income | -435M | -424M | 141M | 117M | 143M | 153M | 147M | 127M | 44.4M | 31.1M |
| EPS | -2.17 | -2.11 | 0.70 | 0.33 | 0.37 | 0.38 | 0.37 | 0.32 | 0.11 | 0.08 |
| Balance Sheet | ||||||||||
| Total Assets | 713M | 856M | 993M | 1.01B | 1.43B | 1.59B | 1.82B | 1.83B | 1.76B | 1.77B |
| Total Liabilities | 66.2M | 80.9M | 126M | 119M | 152M | 211M | 432M | 416M | 350M | 343M |
| Shareholders' Equity | 647M | 775M | 867M | 887M | 1.28B | 1.38B | 1.39B | 1.42B | 1.41B | 1.43B |
| Cash & Short-term Investments | 160M | 77.2M | 583M | 553M | 925M | 985M | 919M | 909M | 106M | 164M |
| Total Debt | - | - | - | 10.2M | 24.6M | 12.5M | 235M | 224M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 133M | 148M | 201M | 152M | 189M | 245M | 173M | 168M | 93.9M | - |
| Capital Expenditure | 59.4M | 48.5M | 55.2M | 83.3M | 72.5M | 125M | 301M | 107M | 69.9M | 25.7M |
| Free Cash Flow | 74.0M | 99.2M | 146M | 68.6M | 116M | 119M | -128M | 60.5M | 24.0M | 79.8M |
| Ratios | ||||||||||
| ROE | -67.3% | -54.7% | 16.2% | 13.2% | 11.2% | 11.1% | 10.6% | 9.0% | 3.1% | 2.2% |
| ROA | -61.0% | -49.5% | 14.2% | 11.6% | 10.0% | 9.6% | 8.1% | 6.9% | 2.5% | 1.8% |
| Net Profit Margin | -136.6% | -115.9% | 30.9% | 28.0% | 30.3% | 32.8% | 33.1% | 29.1% | 13.3% | 10.1% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.17x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chemclin Diagnostics Co. Ltd. A dividends
- Dividend yield
- 2.35%
- Forward dividend
- -
- Payout ratio
- 123.4%
- Ex-dividend date
- Jun 13, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 54.8M | 0.14 | 123.4% |
| 2024 | CNY 53.3M | 0.13 | 41.9% |
| 2023 | CNY 139M | 0.35 | 94.4% |
| 2022 | CNY 68.2M | 0.17 | 44.7% |
| 2021 | - | - | - |
| 2020 | CNY 100M | 0.28 | 85.5% |
| 2019 | CNY 41.6M | 0.21 | 29.6% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Chemclin Diagnostics Co. Ltd. A
- Insiders 45.81%
- Institutions 9.84%
- Public & others 44.34%
- Shares outstanding 401M
- Free float 208M
Chemclin Diagnostics Co. Ltd. A company profile
- Company name
- Chemclin Diagnostics Co. Ltd. A
- Ticker
- 688468.SHG
- ISIN
- CNE100005311
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 580
- Fiscal year end
- December
- Address
- Incubation Bldg, Beijing, China, 100094
- Phone
- 86 10 5871 7511
- Website
- chemclin.com
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sale of clinical immuno chemiluminescence diagnostic reagents and instruments in China. The company offers the LiCA series of diagnostic reagents, which is based on photo-induced chemiluminescence; the Chemclin series of diagnostic reagents and instruments, which is based on enzyme-catalyzed chemiluminescence; and routine clinical chemistry diagnostic reagents. Its products are used for the detection of biomarkers for infectious diseases, such as hepatitis B, hepatitis C, HIV, syphilis, hepatitis A, and hepatitis E, etc., as well as of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company serves large and medium-sized hospitals, health check-up centers, emergency rooms, clinical laboratories, emergency departments, chest pain centers, and community centers. Chemclin Diagnostics Co., Ltd. was founded in 2005 and is headquartered in Beijing, China.
Chemclin Diagnostics Co. Ltd. A management
6- Mr. Lin LiChairman & GM · born 1962
- Ms. Yanling HuangCFO, Secretary & Director · born 1975
- Mr. Zheng Ming HuangDeputy GM & Director · born 1970
- Li JinAccounting Supervisor
- Mr. Zifu LianCore Technical Personnel · born 1968
- Ms. Yu Hui LiuCore Technical Personnel · born 1971